Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
Marginal Zone LymphomaFollicular Lymphoma
Interventions
DRUG

HMPL-689

All patients are to receive monotherapy of HMPL-689 30 mg QD continuously in 28-day treatment cycles.

Trial Locations (58)

30002

Shanxi Bethune Hospital, Taiyuan

100020

Beijing Chao-yang Hospital, Capital Medical University, Beijing

100050

Beijing Friendship Hospital, Capital Medical University, Beijing

100191

Peking University Third Hospital, Beijing

130000

The First Hospital of Jilin University, Changchun

200092

Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

200433

Fudan University Shanghai Cancer Center, Shanghai

226001

The First People's Hospital of Nantong, Nantong

230601

The Second Hospital of Anhui Medical University, Hefei

266000

The affiliated hospital of Qingdao University, Qingdao

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310003

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

310022

Zhejiang Cancer Hospital, Hangzhou

325000

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

330006

The First Affiliated Hospital of Nanchang University, Nanchang

350014

Fujian Cancer Hospital, Fuzhou

361001

The First Affiliated Hospital of Xiamen University, Xiamen

400030

Chongqing University Cancer Hospital, Chongqing

410013

Hunan Cancer Hospital, Changsha

410900

Puyang Oilfield General Hospital, Puyang

425006

The Central Hospital of YongZhou, Yongzhou

430000

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

430061

People's Hospital of Wuhan University, Wuhan

450003

Henan Cancer Hospital, Zhengzhou

Henan Provincial People's Hospital, Zhengzhou

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510060

Sun Yat-sen University Cancer Center, Guangzhou

510515

Nanfang Hospital, Southern Medical University, Guangzhou

515031

Cancer Hospital of Shantou University Medical College, Shantou

530021

Guangxi Medical University Affiliated Tumor Hospital, Nanning

570311

Hainan General Hospital, Haikou

610041

West China Hospital Sichuan University, Chengdu

637000

Affiliated Hospital of North Sichuan Medical College, Nanchong

830000

Cancer Hospital Affiliated to Xinjiang Medical University, Ürümqi

Unknown

Beijing GoBroad Boren Hospital, Beijing

Beijing Tongren Hospital, Capital Medical University, Beijing

The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai

Affiliated Hospital of Chengde Medical University, Chengde

The Fourth Hospital of Hebei Medical University, Shijiazhuang

Xingtai People's Hospital, Xingtai

The First Affiliated Hospital of Harbin Medical University, Harbin

The First Hospital of Harbin, Harbin

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

The Second Xiangya Hospital of Central South University, Changsha

The Second People's Hospital of Huaihua, Huaihua

The Second Affiliated Hospital of Suzhou University, Suzhou

The First Affiliated Hospital of Gannan Medical University, Gannan

Ganzhou People's Hospital, Ganzhou

Jiangxi Provincial Cancer Hospital, Nanchang

The First Affiliated Hospital of Jinzhou Medical University, Jinzhou

Shengjing Hospital of China Medical University, Shengyang

Affiliated Hospital of Binzhou Medical University, Binzhou

Jinan Central Hospital, Jinan

Qilu Hospital of Shandong University, Jinan

Shanghai East Hospital, Tongji University School of Medicine, Shanghai

The First Hospital of Shanxi Medical University, Taiyuan

First Affiliated Hospital of Kunming Medical University, Kunming

Yunnan Cancer Hospital, Kunming

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY